A cyclic polypeptide, derivative or analogue thereof, comprising an amino acid sequence derived from the C-terminus of acetylcholinesterase (AChE), or a truncation thereof.

The invention relates to biomarkers, and particularly, although not exclusively, to biomarkers for neurodegenerative disorders, such as Alzheimer's disease, Parkinson's disease, Huntington's disease or Motor Neurone disease. The invention especially relates to novel biomarkers for facilitating Braak staging for classifying the degree of pathology in Alzheimer's disease in living patients, and determining the need or otherwise of Positron Emission Topography (PET) scanning for detecting the presence of beta amyloid in the brain. The invention further provides diagnostic and prognostic methods and kits for neurodegenerative disorders, and for Braak staging and determining the need for conducting a PET scan on a subject suspected of suffering from Alzheimer's disease.

Nucleic acid agents for reducing or removing infestations of the Varroa destructor mite are described. Compositions comprising the nucleic acid agents and methods for controlling mite infestations using the nucleic acid agents and compositions are also disclosed.

A method for designing and selecting a protein having a stabilized structure compared to a corresponding wild type protein, and proteins having at least six amino acid substitutions with respect to a corresponding wild type protein, designed for improved thermal stability, improved specific activity and/or improved expression levels, are provided herein.

The present invention relates to the present invention provides novel recombinant protein produced from cholinesterase gene derived from Pseudomonas aeruginosa and the composition comprising the same for treating or preventing a neurological disease.

The present invention provides a method form making a composition of nanoparticles comprising a biological mimetic base component that forms the structure of the nanoparticle. By interacting with the functional groups of the base component, the half-life of a bioactive molecule is extended.

Methods for quantitating viral capsids and/or polynucleotides contained therein using a charged biopolymer-loaded biosensor are provided. The signals indicative of binding of molecules (such as polynucleotides or viral capsids) to the biosensor can be measured by bio-layer interferometry (BLI). The amount of viral capsids can be calculated based on signals indicative of binding of the viral capsids to the biosensor. The empty/full viral capsid ratio in a viral sample can be calculated based on the amount of the viral polynucleotides and/or the binding kinetics of the biosensor to the viral capsids or the polynucleotides.